Looks like it is “round two” between Relmada Therapeutics and Laidlaw. Recently, Relmada Therapeutics filed a lawsuit against Laidlaw and its principals, Matthew Einer and James Ahern. Relmada originally claimed that Matthew Einer and James Ahern were engaged in spreading “false and misleading material”, in regards to the company. A temporary order was put in place for Laidlaw and its principals to cease spreading information about Relmada Therapeutics.

The second act of this saga includes, Relmada Therapeutics filing an amendment. No, not the good kind of amendment either. In addition to the original complaint, Relmada is now accusing Laidlaw and its principals of breaching its fiduciary duty to Relmada.

Laidlaw specializes in the finance and wealth management for businesses and institutions. They focus much of their fiscal expertise on healthcare organizations. Hence, Laidlaw was involved with Relmada and played the role of investment bank to Relmada Therapeutics. In this capacity, releasing any confidential financial information to other organizations or individuals could threaten Relmada’s survivability as a business. Actions like this may also lead to a “hostile takeover” now that the competition has insider information on the financial state and plans of Relmada Therapeutics.

Any way you look at it, Laidlaw has put Relmada Therapeutics at great risk with their reckless behavior. Relmada is currently researching and producing alternatives to opioids in pain management as well as addiction recovery. Personally, I believe the people at Relmada have something wonderful to off the world of medicine. However, my fear is that Relmada Therapeutics “alternatives” may not be “lining the pockets” of the competition and the competition is not happy about this.

Since the inception of Matthew Einer and James Ahern, Laidlaw has been investing on the other side of the law, it seems. A long history of dishonest behavior and mistrust cloud the reputation of Laidlaw, for now. Maybe, its time to “take a fall” in “round two”, gentlemen. Time for Mr. Einer and Mr. Ahern to “throw in the towel”.

A Brief Introduction To Laidlaw

According to the company’s own website, Laidlaw is a private investment banking firm. The site claims that Laidlaw was established in 1842. Services offered by Laidlaw include wealth management, alternative investments and capital markets.

Wealth management services by the firm includes traditional financial planning such as preparing for retirement and setting up trusts and estates. It also includes portfolio management to grow client wealth. Laidlaw alternative investments involves pooling client capital to invest in technology, media and transportation companies that are often overlooked.

Capital markets through Laidlaw include traditional investment banking services such as assistance with mergers and acquisitions and the sale of company stock. Also covered under capital markets is the trading department of the firm and its research division. The trading department buys and sells commodities and bonds for clients. The research division includes two full time analysts who look at up and coming investment opportunities in technology, healthcare and energy.

Corrupt And Shady Employees At The Firm

Laidlaw also known as Laidlaw Ltd. is led by Matthew Eitner and James Ahern. Both of them were mentioned in a lawsuit filed against Laidlaw by by biotechnology company, Relmada Therapeutics in the Nevada Federal District Court. The lawsuit alleges that both Matthew Eitner and James Ahern helped spread false information that sent stocks of company share plummeting. Ahern and Eitner also tried to takeover the company by extortion. They threatened to appoint the majority of board members at Relmada if the company decided to terminate the relation with Laidlaw.

A restraining order has been placed on Laidlaw and James Ahern and Matthew Eitner by the US District Court Of Nevada. It is important to point out that James Ahern has had multiple consumer complaints filed against him as well as failure to pay taxes. Each complaint and case was settled with compensation paid to the party filing the complaint.

Remalda Therapeutics announced recently that they were filing a lawsuit against Laidlaw & Company UK. Remalda develops therapies for people suffering from chronic pain. They are filing their lawsuit against Laidlaw in the U.S. District Court in Nevada. Remalda hopes that the lawsuit will help them regain much of what they lost by working with Laidlaw.

The lawsuit against Laidlaw features several important complaints. Remalda claims that Laidlaw breached their fiduciary duty by disclosing confidential information when they started working as Remalda’s investment banking. Remalda is seeking monetary damages from the fees and costs that were incurred responding to Laidlaw’s materials.

Remalda has had great success working in the courts to get reparations. The Nevada court has already issued a restraining order in another case against Laidlaw. Remalda wants compensation for the damages that Laidlaw has inflicted on them.The company has issued a press release and sent a notice to their stockholders. They are very confident that the lawsuit will end in their favor.

Laidlaw and Company are a full-service investment banking and brokerage firm. The company is lead by principals Matthew Eitner and James Aherm. The company has a 170-year history of serving their customers with integrity, but in recent years the firm has gone down hill. Laidlaw is fending off multiple lawsuits, including the one from Remalda. Additionally, several workers have complained of the harsh working conditions at Laidlaw. The company earns a mere three stars on Glassdoor. They don’t help their interns reach their potential and have been accused of taking advantage of their work ethic. Laidlaw is heading downhill if they do not take action soon.

Remalda is struggling because they trusted Laidlaw and Company. Fortunately, it looks like Laidlaw is making progress within the United States courts. The issue should be rectified soon and Eitner and Aherm will be punished.